Reduced protein solubility - cause or consequence in amyloid disease?

Area of Science:

• Neuroscience
• Biochemistry
• Physical Chemistry

Background:

• Amyloid diseases, such as Alzheimer's disease, are characterized by protein deposition.
• A reduction in cerebrospinal fluid (CSF) concentration of amyloid beta peptide, specifically Aβ42, is often observed in Alzheimer's disease patients.

Purpose of the Study:

• To investigate whether the observed lower solubility of specific proteins, particularly Aβ42, is a cause or a consequence of protein deposition in amyloid diseases.
• To explore potential physicochemical explanations for reduced Aβ42 concentrations in CSF.

Main Methods:

• Review of experimental evidence regarding Aβ42 concentrations in CSF.
• Analysis of physicochemical principles governing protein solubility and aggregation.
• Theoretical exploration of metastable states in protein solutions.

Main Results:

• Several physicochemical explanations for reduced Aβ42 levels are proposed, including true reduced solubility and reduced apparent solubility.
• The concept of a long-lived metastable state for Aβ42 is introduced, where concentrations exceed solubility limits without immediate precipitation.
• The study evaluates whether these scenarios represent a cause or consequence of Aβ42 deposition.

Conclusions:

• The observed reduction in CSF Aβ42 levels in Alzheimer's disease may stem from various physicochemical phenomena, not solely a direct cause-effect relationship with deposition.
• Understanding these states is crucial for differentiating between cause and consequence in Aβ42 pathology.
• Further research is needed to elucidate the precise mechanisms driving Aβ42 behavior in Alzheimer's disease.